Although the trial closed prematurely and definitive statements regarding the efficacy of adjuvant gefitinib cannot be made, these results indicate that it is unlikely to be of benefit.
No takes yet. Share an insight, caveat, or question.
Goss et al. (2013) studied this question.
Synapse has enriched one closely related paper. Consider it for comparative context: